Takahiro Kodama

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5386972/publications.pdf

Version: 2024-02-01

84 papers 2,848 citations

201385 27 h-index 50 g-index

86 all docs 86 docs citations

86 times ranked 4874 citing authors

#	Article	IF	Citations
1	The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. Journal of Hepatology, 2010, 52, 698-704.	1.8	320
2	Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. International Journal of Cancer, 2012, 131, 548-557.	2.3	230
3	Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice. Journal of Clinical Investigation, 2011, 121, 3343-3356.	3.9	138
4	The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. Hepatology, 2010, 52, 1310-1321.	3.6	126
5	Thrombocytopenia Exacerbates Cholestasis-Induced Liver Fibrosis in Mice. Gastroenterology, 2010, 138, 2487-2498.e7.	0.6	111
6	Mcl-1 and Bcl-xL cooperatively maintain integrity of hepatocytes in developing and adult murine liver. Hepatology, 2009, 50, 1217-1226.	3.6	106
7	Alterations in microRNA expression profile in HCV-infected hepatoma cells: Involvement of miR-491 in regulation of HCV replication via the PI3 kinase/Akt pathway. Biochemical and Biophysical Research Communications, 2011, 412, 92-97.	1.0	88
8	In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E7301-E7310.	3.3	88
9	BH3-only Activator Proteins Bid and Bim Are Dispensable for Bak/Bax-dependent Thrombocyte Apoptosis Induced by Bcl-xL Deficiency. Journal of Biological Chemistry, 2011, 286, 13905-13913.	1.6	78
10	CTGF Mediates Tumor–Stroma Interactions between Hepatoma Cells and Hepatic Stellate Cells to Accelerate HCC Progression. Cancer Research, 2018, 78, 4902-4914.	0.4	75
11	Transcriptomics Identify Thrombospondinâ€2 as a Biomarker for NASH and Advanced Liver Fibrosis. Hepatology, 2021, 74, 2452-2466.	3.6	71
12	Mcl-1 and Bcl-xL regulate Bak/Bax-dependent apoptosis of the megakaryocytic lineage at multistages. Cell Death and Differentiation, 2012, 19, 1856-1869.	5 . 0	59
13	Transposon mutagenesis identifies genes and cellular processes driving epithelial-mesenchymal transition in hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E3384-93.	3.3	56
14	Exosomal micro <scp>RNA</scp> s derived from colon cancer cells promote tumor progression by suppressing fibroblast <i><scp>TP</scp>53</i> <ep>i> expression. Cancer Science, 2019, 110, 2396-2407.</ep>	1.7	55
15	Bak deficiency inhibits liver carcinogenesis: A causal link between apoptosis and carcinogenesis. Journal of Hepatology, 2012, 57, 92-100.	1.8	54
16	Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma. Hepatology, 2023, 77, 77-91.	3.6	50
17	Transposon mutagenesis identifies genes that cooperate with mutant Pten in breast cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7749-E7758.	3.3	48
18	Molecular profiling of nonalcoholic fatty liver disease-associated hepatocellular carcinoma using SB transposon mutagenesis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E10417-E10426.	3.3	47

#	Article	IF	Citations
19	DNase II activated by the mitochondrial apoptotic pathway regulates RIP1-dependent non-apoptotic hepatocyte death via the TLR9/IFN- \hat{l}^2 signaling pathway. Cell Death and Differentiation, 2019, 26, 470-486.	5.0	42
20	Estrogen therapy initiated at an early age increases bone mineral density in Turner syndrome patients. Endocrine Journal, 2012, 59, 153-159.	0.7	40
21	Analyzing tumor heterogeneity and driver genes in single myeloid leukemia cells with SBCapSeq. Nature Biotechnology, 2016, 34, 962-972.	9.4	40
22	p53 functional deficiency in human colon cancer cells promotes fibroblast-mediated angiogenesis and tumor growth. Carcinogenesis, 2016, 37, 972-984.	1.3	40
23	Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy. Cancers, 2022, 14, 883.	1.7	38
24	Frequency of, and factors associated with, hepatitis B virus reactivation in hepatitis C patients treated with allâ€oral directâ€acting antivirals: Analysis of a Japanese prospective cohort. Hepatology Research, 2017, 47, 1438-1444.	1.8	36
25	Absence of invariant natural killer T cells deteriorates liver inflammation and fibrosis in mice fed high-fat diet. Journal of Gastroenterology, 2010, 45, 1247-1254.	2.3	35
26	Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study. Journal of Gastroenterology, 2021, 56, 67-77.	2.3	34
27	Incidence and risk factors of hepatocellular carcinoma change over time in patients with hepatitis C virus infection who achieved sustained virologic response. Hepatology Research, 2019, 49, 570-578.	1.8	32
28	Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy. Hepatology Research, 2022, 52, 298-307.	1.8	31
29	Pancreatic STAT3 Protects Mice against Caerulein-Induced Pancreatitis via PAP1 Induction. American Journal of Pathology, 2012, 181, 2105-2113.	1.9	30
30	Identification of New Tumor Suppressor Genes in Triple-Negative Breast Cancer. Cancer Research, 2017, 77, 4089-4101.	0.4	28
31	GREB1 induced by Wnt signaling promotes development of hepatoblastoma by suppressing TGF \hat{l}^2 signaling. Nature Communications, 2019, 10, 3882.	5 . 8	28
32	Two-Step Forward Genetic Screen in Mice Identifies RalÂGTPase-Activating Proteins as Suppressors of HepatocellularÂCarcinoma. Gastroenterology, 2016, 151, 324-337.e12.	0.6	27
33	Delayed-onset caspase-dependent massive hepatocyte apoptosis upon fas activation in bak/bax-deficient mice. Hepatology, 2011, 54, 240-251.	3.6	26
34	Carbamazepine promotes liver regeneration and survival in mice. Journal of Hepatology, 2013, 59, 1239-1245.	1.8	26
35	Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma. Hepatology Research, 2022, 52, 630-640.	1.8	25
36	Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination Immunotherapy. Cancers, 2022, 14, 3367.	1.7	24

#	Article	IF	CITATIONS
37	BH3-only protein bid participates in the Bcl-2 network in healthy liver cells. Hepatology, 2009, 50, 1972-1980.	3.6	23
38	Activation of the Mitochondrial Apoptotic Pathway Produces Reactive Oxygen Species and Oxidative Damage in Hepatocytes That Contribute to Liver Tumorigenesis. Cancer Prevention Research, 2015, 8, 693-701.	0.7	23
39	MRTFB suppresses colorectal cancer development through regulating SPDL1 and MCAM. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 23625-23635.	3.3	22
40	Constitutive Activation of the Tumor Suppressor p53 in Hepatocytes Paradoxically Promotes Non–Cell Autonomous Liver Carcinogenesis. Cancer Research, 2022, 82, 2860-2873.	0.4	22
41	Efficacy of Dienogest in Thinning the Endometrium Before Hysteroscopic Surgery. Journal of Minimally Invasive Gynecology, 2013, 20, 790-795.	0.3	21
42	Nonstructural protein 5A/P32 deletion after failure of ledipasvir/sofosbuvir in hepatitis C virus genotype 1b infection. Hepatology, 2018, 68, 380-383.	3.6	18
43	CRISPR Loss-of-Function Screen Identifies the Hippo Signaling Pathway as the Mediator of Regorafenib Efficacy in Hepatocellular Carcinoma. Cancers, 2019, 11, 1362.	1.7	18
44	Hepatitis C virus infection suppresses hepatitis B virus replication via the RIG-I-like helicase pathway. Scientific Reports, 2020, 10, 941.	1.6	18
45	Interleukin- $1\hat{l}^2$ enhances the production of soluble MICA in human hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2012, 61, 1425-1432.	2.0	17
46	Involvement of STAT3-regulated hepatic soluble factors in attenuation of stellate cell activity and liver fibrogenesis in mice. Biochemical and Biophysical Research Communications, 2011, 406, 614-620.	1.0	15
47	Interferon-α suppresses hepatitis B virus enhancer II activity via the protein kinase C pathway. Virology, 2012, 432, 452-459.	1.1	15
48	Invariant natural killer T cell deficiency leads to the development of spontaneous liver inflammation dependent on Î3ÎT cells in mice. Journal of Gastroenterology, 2015, 50, 1124-1133.	2.3	15
49	Clinical outcomes of directâ€acting antiviral treatments for patients with hepatitis C after hepatocellular carcinoma are equivalent to interferon treatment. Hepatology Research, 2020, 50, 1118-1127.	1.8	15
50	Dysregulation of PI3K and Hippo signaling pathways synergistically induces chronic pancreatitis via CTGF upregulation. Journal of Clinical Investigation, 2021, 131, .	3.9	15
51	The Bcl-2 Homology Domain 3 (BH3)-only Proteins Bim and Bid Are Functionally Active and Restrained by Anti-apoptotic Bcl-2 Family Proteins in Healthy Liver*. Journal of Biological Chemistry, 2013, 288, 30009-30018.	1.6	14
52	Efficacy of hormone therapy for osteoporosis in adolescent girls after hematopoietic stem cell transplantation: a longitudinal study. Fertility and Sterility, 2011, 95, 731-735.	0.5	12
53	Synthetic lethal interaction of combined <scp>CD26</scp> and <scp>Bclâ€xL</scp> inhibition is a powerful anticancer therapy against hepatocellular carcinoma. Hepatology Research, 2015, 45, 1023-1033.	1.8	12
54	Circulating tricarboxylic acid cycle metabolite levels in citrin-deficient children with metabolic adaptation, with and without sodium pyruvate treatment. Molecular Genetics and Metabolism, 2017, 120, 207-212.	0.5	12

#	Article	IF	Citations
55	Forkhead Box M1 Transcription Factor Drives Liver Inflammation Linking to Hepatocarcinogenesis in Mice. Cellular and Molecular Gastroenterology and Hepatology, 2020, 9, 425-446.	2.3	12
56	The combination therapy of $\hat{l}\pm\hat{a}$ galactosylceramide and $5\hat{a}$ fluorouracil showed antitumor effect synergistically against liver tumor in mice. International Journal of Cancer, 2013, 133, 1126-1134.	2.3	11
57	Soluble UL16-binding protein 2 is associated with a poor prognosis in pancreatic cancer patients. Biochemical and Biophysical Research Communications, 2019, 517, 84-88.	1.0	11
58	Autophagy impairment in pancreatic acinar cells causes zymogen granule accumulation and pancreatitis. Biochemical and Biophysical Research Communications, 2018, 503, 2576-2582.	1.0	10
59	Clinical course of hepatitis C virusâ€positive patients with decompensated liver cirrhosis in the era of directâ€acting antiviral treatment. Hepatology Research, 2021, 51, 517-527.	1.8	10
60	Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis. Hepatology Research, 2022, 52, 824-832.	1.8	10
61	Hepatocellular carcinoma occurrence does not differ between interferonâ€based and interferonâ€free treatment with liver histological assessment. Hepatology Research, 2020, 50, 313-320.	1.8	9
62	SIRT1 enhances hepatitis virus B transcription independent of hepatic autophagy. Biochemical and Biophysical Research Communications, 2020, 527, 64-70.	1.0	9
63	Valine, the branched-chain amino acid, suppresses hepatitis C virus RNA replication but promotes infectious particle formation. Biochemical and Biophysical Research Communications, 2013, 437, 127-133.	1.0	8
64	Hypovascular hepatic nodules as a predictive factor for transcatheter arterial chemoembolization refractoriness in hepatocellular carcinoma. Hepatology Research, 2020, 50, 365-373.	1.8	8
65	TNF receptor–related factor 3 inactivation promotes the development of intrahepatic cholangiocarcinoma through NFâ€₽Bâ€inducing kinase–mediated hepatocyte transdifferentiation. Hepatology, 2023, 77, 395-410.	3.6	7
66	Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice. Journal of Gastroenterology, 2019, 54, 449-458.	2.3	6
67	Hepatitis C virus modulates signal peptide peptidase to alter host protein processing. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118 , .	3.3	6
68	Inhibition of nonhomologous end joiningâ€mediated DNA repair enhances antiâ€HBV CRISPR therapy. Hepatology Communications, 2022, 6, 2474-2487.	2.0	6
69	Cholesterol Metabolism Is Enhanced in the Liver and Brain of Children With Citrin Deficiency. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2488-2497.	1.8	5
70	Capsid Allosteric Modulators Enhance the Innate Immune Response in Hepatitis B Virus–Infected Hepatocytes During Interferon Administration. Hepatology Communications, 2022, 6, 281-296.	2.0	5
71	Ring Finger Protein 125 Is an Anti-Proliferative Tumor Suppressor in Hepatocellular Carcinoma. Cancers, 2022, 14, 2589.	1.7	5
72	Cotreatment with lenvatinib and warfarin potassium caused prothrombin time prolongation. Hepatology Research, 2019, 49, 1357-1361.	1.8	4

#	Article	IF	CITATIONS
73	Predictive factors of anemia during sofosbuvir and ribavirin therapy for genotype 2 chronic hepatitis C patients. Hepatology Research, 2019, 49, 853-859.	1.8	4
74	Initial treatment response to transarterial chemoembolization as a predictive factor for Child–Pugh class deterioration prior to refractoriness in hepatocellular carcinoma. Hepatology Research, 2020, 50, 1275-1283.	1.8	3
75	Hepatocellular carcinoma due to a baffle obstruction after the mustard operation: A case report. Hepatology, 2018, 67, 2471-2473.	3.6	2
76	Immunological responses against hepatitis B virus in human peripheral blood mononuclear cell-engrafted mice. Biochemical and Biophysical Research Communications, 2018, 503, 1457-1464.	1.0	2
77	Fatal exacerbation of type B chronic hepatitis triggered by changes in relaxed circular viral DNA synthesis and virion secretion. Biochemical and Biophysical Research Communications, 2010, 394, 87-93.	1.0	1
78	Spontaneous closure of an intrahepatic arterioportal fistula: A case report. Acta Hepatologica Japonica, 2017, 58, 393-400.	0.0	1
79	Hepatocellular carcinoma in a case of Wilson's disease with non-cirrhotic liver. Acta Hepatologica Japonica, 2017, 58, 519-527.	0.0	1
80	Therapeutic efficacy of lenvatinib in hepatocellular carcinoma patients with portal hypertension. Hepatology Research, 2020, 50, 1091-1100.	1.8	1
81	Activation of p53 After Irradiation Impairs the Regenerative Capacity of the Mouse Liver. Hepatology Communications, 2022, 6, 411-422.	2.0	1
82	Prognostic impact of worsening of esophageal varices after balloonâ€occluded retrograde transvenous obliteration. Journal of Gastroenterology and Hepatology (Australia), 2022, , .	1.4	1
83	Reply. Hepatology, 2022, 75, 1058-1058.	3.6	0
84	Reply. Hepatology, 2022, 75, 1341-1341.	3.6	0